Intravenous immunoglobulin and plasma exchange prescribing patterns for Guillain‐Barre Syndrome in the United States—2001 to 2018
Repeat IVIG dosing was quite common in GBS before newer trials suggesting harm in non-responders, and IVIG/PLEX combination therapy continues to persist despite strong evidence against use in non-responders. Further, nearly one in three patients initially diagnosed with GBS is subsequently diagnosed with CIDP, but the reasons are unclear.
Authors
- Amro Maher Stino (ORCID: https://orcid.org/0000-0002-7793-6662)
- Brian C. Callaghan (ORCID: https://orcid.org/0000-0002-8885-6748)
- Evan L. Reynolds (ORCID: https://orcid.org/0000-0002-0138-8436)
- Maya Watanabe (ORCID: https://orcid.org/0009-0007-3309-2852)
Institutions
- University of Michigan (US)
Publication Details
- Journal
- Muscle & Nerve
- Published
- 2024-09-26
- DOI
- https://doi.org/10.1002/mus.28265
- Citations
- 3
- Primary Topic
- Peripheral Neuropathies and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.11
Funders
- Bristol-Myers Squibb
- GBS/CIDP Foundation International
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases